We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Approves Thermo Fisher Test to ID NSCLC Patients Who May Benefit from Janssen’s Rybrevant
FDA Approves Thermo Fisher Test to ID NSCLC Patients Who May Benefit from Janssen’s Rybrevant
The FDA has granted premarket approval to Thermo Fisher Scientific's Oncomine Dx Target Test as a companion diagnostic to help identify nonsmall-cell lung cancer (NSCLC) patients whose tumors carry certain mutations for potential treatment with Rybrevant (amivantamab-vmjw), Janssen’s targeted therapy.